A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

NCT Number	NCT07548060
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	NSCLC Stage IV, EGFR Gene Mutation
Enrollment	25 participants
Start Date	2026-02-01
Primary Completion	2028-01-22 (estimated)
Study Completion	2028-01-22 (estimated)
Updated on ClinicalTrials.gov	2026-04-23